Pyxis Oncology (PYXS) & Its Competitors Financial Analysis

Pyxis Oncology (NASDAQ:PYXS) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Pyxis Oncology to related companies based on the strength of its profitability, analyst recommendations, valuation, risk, earnings, dividends and institutional ownership.

Volatility and Risk

Pyxis Oncology has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500. Comparatively, Pyxis Oncology’s peers have a beta of 1.11, meaning that their average stock price is 11% more volatile than the S&P 500.

Earnings & Valuation

This table compares Pyxis Oncology and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Pyxis Oncology	$13.86 million	-$79.62 million	-1.28
Pyxis Oncology Competitors	$689.46 million	$10.37 million	-10.05

Pyxis Oncology’s peers have higher revenue and earnings than Pyxis Oncology. Pyxis Oncology is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

39.1% of Pyxis Oncology shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 5.7% of Pyxis Oncology shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Pyxis Oncology and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-215.23%	-112.19%
Pyxis Oncology Competitors	-9,054.31%	-198.21%	-30.53%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Pyxis Oncology and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1	1	8	0	2.70
Pyxis Oncology Competitors	9770	15029	45237	1570	2.54

Pyxis Oncology presently has a consensus price target of $8.75, suggesting a potential upside of 383.43%. As a group, “Biotechnology” companies have a potential upside of 95.44%. Given Pyxis Oncology’s stronger consensus rating and higher probable upside, analysts plainly believe Pyxis Oncology is more favorable than its peers.

Summary

Pyxis Oncology peers beat Pyxis Oncology on 7 of the 12 factors compared.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.